All Updates

All Updates

icon
Filter
Partnerships
Clario partners with PathAI to enhance GI clinical trials with integrated digital solutions
Clinical Trial Technology
Oct 10, 2024
This week:
Partnerships
Apple discloses use of AWS GenAI chips at re:Invent 2024 conference
Generative AI Infrastructure
Today
Product updates
AWS launches Automated Reasoning checks to combat AI hallucinations
Generative AI Infrastructure
Today
Product updates
Roonyx releases enhanced BNPL platform to facilitate secure transactions
Buy Now, Pay Later
Yesterday
Product updates
AWS announces next generation of SageMaker platform at re:Invent 2024
Generative AI Infrastructure
Yesterday
Product updates
Equal1 launches quantum controller chip for cryogenic computing
Quantum Computing
Yesterday
Partnerships
Exotec partners with BlueStar to deploy Skypod warehouse automation system
Logistics Tech
Yesterday
Partnerships
Amaero enters long-term supply agreement with Perryman
Additive Manufacturing
Yesterday
Product updates
Raise3D launches six new resins for DF2 DLP solution
Additive Manufacturing
Yesterday
M&A
Anzu Partners acquires voxeljet for EUR 20 million
Additive Manufacturing
Yesterday
Funding
Soda Health raises USD 50 million in oversubscribed Series B funding to scale operations
Health Benefits Platforms
Yesterday
Clinical Trial Technology

Clinical Trial Technology

Oct 10, 2024

Clario partners with PathAI to enhance GI clinical trials with integrated digital solutions

Partnerships

  • Clario, a provider of endpoint data solutions, has partnered with PathAI, an AI-powered digital pathology solutions company, to improve gastrointestinal (GI) clinical trials.

  • The partnership aims to offer a single-vendor solution that combines Clario's advanced imaging solutions like endoscopy with PathAI's AI-powered histopathology services. This integrated approach will streamline endoscopic and histopathology end points, improving efficiency in global GI studies.

  • The collaboration will benefit CROs, sponsors, and investigational sites by providing simplified workflows, improved training, reporting, and document management. It is expected to enhance diagnostic accuracy, boost efficiency, and enable reliable turnaround times in GI clinical trials, particularly for inflammatory bowel disease (IBD) and ulcerative colitis (UC) studies.

  • Analyst QuickTake: This marks the second partnership Clario has secured in 2024. In August , the company partnered with Mobilise-D consortium to integrate Mobilise-D's validated algorithms into Clario's Opal wearable sensor system, enabling real-world mobility assessments for patients. Partnerships such as those secured with PathAI and with Mobilise-D help Clrio to expand both the platform’s functionality along with its market presence in the clinical trial space.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.